Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

Nat Med. 2025 Jun 26. doi: 10.1038/s41591-025-03852-y. Online ahead of print.

Yago Nieto¹, Pinaki Banerjee^{2

3}, Indreshpal Kaur², Rafet Basar^{2

3}, Ye Li^{2

3}, May Daher^{2

3}, Hind Rafei^{2

3}, Lucila N Kerbauy², Mecit Kaplan^{2

3}, David Marin^{2

3}, Lori Griffin², Melissa Barnett², Roland Bassett⁴, Nadima Uprety^{2

3}, Rejeena Shrestha^{2

3}, Francia Reyes Silva^{2

3}, Sanjida Islam^{2

3}, Christina Ganesh², Zephanie Borneo², Jeremy Ramdial², Alejandro Ramirez², Chitra Hosing², Amin Alousi², Uday Popat², Muzaffar Qazilbash², Sairah Ahmed⁵, Swaminathan Iyer⁵, Tania P Sainz⁶, Francisco Vega⁶, Natalie W Fowlkes⁷, Karenza Alexis⁸, Michael Emig⁸, Andreas Harstrick⁸, Andre Overesch⁸, Elizabeth J Shpall², Katayoun Rezvani^{2

3}

¹ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ynieto@mdanderson.org.
² Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Institute for Cell Therapy Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁷ Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Affimed GmbH, Heidelberg, Germany.

No abstract available

Publication types